Publication | Closed Access

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

Cetuximab Versus FolfiriGastrointestinal OncologyTumour DynamicsMedicineCancer ManagementColorectal CancerPathologyMetastatic Colorectal CancerCancer TreatmentOncologyRadiation OncologyCancer ResearchMolecular Oncology